ISSWSH ISSUES IMPORTANT UPDATES FOR HSDD THERAPIES

ISSWSH is pleased to provide the following updates related to therapies for Hypoactive Sexual Desire Disorder or HSDD. The FDA has updated prescribing information for flibanserin, removed the REMS certification requirement for prescribers and pharmacists, and updated safety information related to the alcohol contraindication. In addition, bremelanotide has now been approved for treatment of HSDD. Please see the attached news release related to these two therapies for more specific information and references.

News Release

Save the Date

ISSWSH Virtual Course 2020
November 6, 13, & 20, 2020  
Virtual
Visit the Course Website

ISSWSH Annual Meeting 2021
March 4-7, 2021   134 days left
Virtual
Visit the Meeting Website

Latest Tweets

We're excited to announce that our 2021 Annual Meeting, scheduled this March in Dallas, is transitioning to a Virtu… https://t.co/RmBUfMGHTb ISSWSH
Not able to join live for the #ISSWSHVirtualCourse? No problem! Registered attendees can watch the recordings on-de… https://t.co/BhBiK7mwrj ISSWSH
Overreaction or appropriate concern? American women consider stockpiling contraceptives https://t.co/Z9Iu2J5RxD ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Us

On Twitter
On Facebook
On Instagram